Efficient Drug Delivery
to the Colon
Colotech Pharma is a pharmaceutical organization that is developing new therapeutic formulations for oral delivery for the treatment of inflammatory bowel diseases and other colon related diseases.
Our technology platform “ColoPulse” makes it possible to efficiently deliver drugs to the affected areas in the colon. Unlike other technologies that suffer from premature or incomplete release, ColoPulse technology platform has been clinically validated and is broadly applicable for small molecules or biological drugs, such as peptides and proteins.
ColoPulse Technology Advantages
Unique Accelerated Release
The different acidity values in the gastrointestinal tract trigger the coating degradation and releases the content in a fast and controlled fashion. This also makes the ColoPulse technology site-specific. The drug delivery is highly reliable since the rate of release is largely independent from the acidity values after degradation has started.
The site-specific release profile has been confirmed in several clinical setups, first using stable isotope experiments and second, with an anti-inflammatory compound used, to treat irritable bowel syndrome (IBS). These clinical studies confirmed that the release of ColoPulse-coated tablets had no influence on food and time of food intake on bioavailability, but also showed that the ColoPulse coating is completely safe to use in humans.
Oral Delivery of Small Molecules
One of the strengths of the ColoPulse technology resides in it's ingredients. ColoPulse thus represents an ideal platform to formulate a wide range of drugs for gastrointestinal delivery. It has been used successfully by the Hospital and Clinical Pharmacy department at the University Medical Centre Groningen (UMCG) to formulate several types of molecules of different sizes, from small ones to biologics.
Colon-targeted Delivery Systems
Oral delivery of substances to the ileocolonic region in the gastrointestinal tract (GIT) is challenging. Local treatment of the colon is required for treating several diseases. This includes inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease, which affect various parts of the GI tract. Mostly these diseases affect the ileum and the ascending colon.
The ascending colon has some advantages compared to other parts of the distal colon. The relative acidic pH that hinders proteolytic activity and the lower bacterial content on top other advantages the colon has such as the long residence time. These advantages make the ascending colon a favorable site of absorption, especially for protein and peptide drugs.